Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)

被引：15

作者：

De Bono, J. S.

Oudard, S.

Ozguroglu, M.

Hansen, S.

Machiels, J. H.

Shen, L.

Matthews, P.

Sartor, A. O.

机构：

[1] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England

[2] Inst Canc Res, Sutton, Surrey, England

[3] Hop Europeen Georges Pompidou, Paris, France

[4] Istanbul Univ, Istanbul, Turkey

[5] Odense Univ Hosp, DK-5000 Odense, Denmark

[6] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium

[7] Sanofi Aventis, Malvern, PA USA

[8] Tulane Univ, New Orleans, LA 70118 USA

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.4508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：2